LV10051B - Method for producing of lyophilized yphosphamide - Google Patents
Method for producing of lyophilized yphosphamide Download PDFInfo
- Publication number
- LV10051B LV10051B LVP-92-174A LV920174A LV10051B LV 10051 B LV10051 B LV 10051B LV 920174 A LV920174 A LV 920174A LV 10051 B LV10051 B LV 10051B
- Authority
- LV
- Latvia
- Prior art keywords
- bis
- die
- und
- der
- ifosfamid
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 229960001101 ifosfamide Drugs 0.000 claims abstract description 39
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000000243 solution Substances 0.000 claims description 34
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000000274 adsorptive effect Effects 0.000 claims description 3
- 241000283070 Equus zebra Species 0.000 claims 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- -1 2-Chlorethyl Chemical group 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical compound N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000008371 Alseis Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-UNTFVMJOSA-N L-iditol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)CO FBPFZTCFMRRESA-UNTFVMJOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N activated carbon Substances [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- CBCIHIVRDWLAME-UHFFFAOYSA-N hexanitrodiphenylamine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O CBCIHIVRDWLAME-UHFFFAOYSA-N 0.000 description 1
- 210000001144 hymen Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cephalosporin Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Control Of El Displays (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Amplifiers (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3637089 | 1986-10-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10051A LV10051A (lv) | 1994-05-10 |
| LV10051B true LV10051B (en) | 1995-06-20 |
Family
ID=6312873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-92-174A LV10051B (en) | 1986-10-31 | 1992-10-27 | Method for producing of lyophilized yphosphamide |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0265812B1 (enExample) |
| JP (1) | JPS63159319A (enExample) |
| KR (1) | KR900003491B1 (enExample) |
| AT (1) | ATE55250T1 (enExample) |
| AU (1) | AU598602B2 (enExample) |
| CA (1) | CA1314231C (enExample) |
| DD (1) | DD262582A5 (enExample) |
| DE (1) | DE3764235D1 (enExample) |
| DK (1) | DK169308B1 (enExample) |
| EG (1) | EG18333A (enExample) |
| ES (1) | ES2017982B3 (enExample) |
| FI (1) | FI87140C (enExample) |
| GE (1) | GEP19971025B (enExample) |
| GR (1) | GR3000708T3 (enExample) |
| HU (1) | HU197987B (enExample) |
| IL (1) | IL84312A (enExample) |
| IN (1) | IN168119B (enExample) |
| LV (1) | LV10051B (enExample) |
| MX (1) | MX8958A (enExample) |
| NO (1) | NO873860L (enExample) |
| PT (1) | PT86032B (enExample) |
| RU (1) | RU1836079C (enExample) |
| UA (1) | UA11075A (enExample) |
| YU (1) | YU197387A (enExample) |
| ZA (1) | ZA878183B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2040394T3 (es) * | 1988-03-19 | 1993-10-16 | Asta Medica Aktiengesellschaft | Procedimiento para preparar un material liofilizado de ifosfamida y mesna. |
| US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
| WO1995007083A1 (en) * | 1993-09-10 | 1995-03-16 | F.H. Faulding & Co. Limited | Ifosfamide lyophilisate composition |
| DE19529057B4 (de) * | 1995-08-08 | 2007-12-13 | Baxter Healthcare S.A. | Ifosfamid-Lyophilisat-Zubereitungen |
| AU757002B2 (en) * | 1998-03-03 | 2003-01-30 | Eli Lilly And Company | Pharmaceutical compositions containing the phospholipase inhibitor sodium ((3-(2-amino-1,2-dioxoethyl)-2-ethyl-1- phenylmethyl)-1H-indol-4-YL)oxy)acetate |
| EA008776B1 (ru) * | 2002-09-05 | 2007-08-31 | Бхарат Сирумс Энд Вэксинс Лтд. | Жидкая стабильная композиция оксазафосфорина с месной |
| DE60332385D1 (de) * | 2002-12-02 | 2010-06-10 | Bharat Serums & Vaccines Ltd | Ifosfamid-zusammensetzungen zur parenteralen verabreichung und verfahren für ihre herstellung |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| EP2071917B1 (en) * | 2006-09-29 | 2012-11-21 | Infa S.A. | Packaging system for pharmaceutical compositions and kit for intravenous administration |
| CN105900385B (zh) * | 2014-12-04 | 2019-08-27 | 华为技术有限公司 | 在数据通信网中的负载分配 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3732340A (en) * | 1966-07-11 | 1973-05-08 | Asta Werke Ag Chem Fab | N',o-propylene phosphoric acid ester diamides |
| DE2750207A1 (de) * | 1977-05-09 | 1978-11-16 | Walton J Smith | Gefriergetrocknete zusammensetzungen, insbesondere gefriergetrocknete pharmazeutische praeparate und verfahren zu deren herstellung |
| DE3279834D1 (en) * | 1981-12-31 | 1989-08-31 | Asta Pharma Ag | 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression |
| US4537883A (en) * | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
-
1987
- 1987-09-15 NO NO873860A patent/NO873860L/no unknown
- 1987-10-20 EP EP87115322A patent/EP0265812B1/de not_active Expired - Lifetime
- 1987-10-20 ES ES87115322T patent/ES2017982B3/es not_active Expired - Lifetime
- 1987-10-20 DE DE8787115322T patent/DE3764235D1/de not_active Expired - Lifetime
- 1987-10-20 AT AT87115322T patent/ATE55250T1/de not_active IP Right Cessation
- 1987-10-23 MX MX895887A patent/MX8958A/es unknown
- 1987-10-26 IN IN837/CAL/87A patent/IN168119B/en unknown
- 1987-10-27 FI FI874727A patent/FI87140C/fi not_active IP Right Cessation
- 1987-10-28 EG EG61687A patent/EG18333A/xx active
- 1987-10-29 UA UA4203570A patent/UA11075A/uk unknown
- 1987-10-29 PT PT86032A patent/PT86032B/pt unknown
- 1987-10-29 RU SU874203570A patent/RU1836079C/ru active
- 1987-10-29 JP JP62272002A patent/JPS63159319A/ja active Granted
- 1987-10-29 IL IL84312A patent/IL84312A/xx not_active IP Right Cessation
- 1987-10-30 KR KR1019870012077A patent/KR900003491B1/ko not_active Expired
- 1987-10-30 CA CA000550706A patent/CA1314231C/en not_active Expired - Lifetime
- 1987-10-30 AU AU80529/87A patent/AU598602B2/en not_active Ceased
- 1987-10-30 YU YU01973/87A patent/YU197387A/xx unknown
- 1987-10-30 DK DK569687A patent/DK169308B1/da not_active IP Right Cessation
- 1987-10-30 DD DD87308471A patent/DD262582A5/de not_active IP Right Cessation
- 1987-10-30 HU HU874900A patent/HU197987B/hu unknown
- 1987-10-30 ZA ZA878183A patent/ZA878183B/xx unknown
-
1990
- 1990-08-09 GR GR90400533T patent/GR3000708T3/el unknown
-
1992
- 1992-10-27 LV LVP-92-174A patent/LV10051B/lv unknown
-
1993
- 1993-07-07 GE GEAP1993972A patent/GEP19971025B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3712768C2 (enExample) | ||
| DE68913075T2 (de) | Stabilisiertes Arzneimittel und Verfahren zu dessen Herstellung. | |
| DE69116135T2 (de) | Verwendung von alpha-tocopherolphosphat oder eines derivates davon zur herstellung kosmetischer dermatologischer oder pharmazeutischer präparate | |
| DE3752112T2 (de) | Verwendung von Inositoltriphosphat zur Behandlung von Entzündungen | |
| EP0617958A1 (en) | Pharmaceutical composition having anti-alcohol, radioprotecting and anti-choleraic activity and stimulating energy metabolism, stomach mucous membrane acid-generation and secretion functions | |
| DE3407823C2 (enExample) | ||
| EP0699442B1 (de) | Die verwendung eines stammes des pilzes fusarium zur herstellung von substanzen und eine darauf basierende zubereitung mit adaptiven und immunmodulierenden eigenschaften | |
| DE3909707A1 (de) | Arzneimittel, geeignet zur einwirkung auf herz und kreislauf | |
| DE3638124C2 (de) | Neue pharmazeutische Verwendung von Ebselen | |
| DE69718422T2 (de) | Pflanzlicher nahrungszusatz zum desodorieren von stuhl und urin | |
| DE2947646A1 (de) | Substanz mit interferon induzierender aktivitaet sowie verfahren zu ihrer herstellung | |
| DE102007057231A1 (de) | Verwendung eines potenten Produktes, extrahiert aus Wurzelstöcken von Zingiber officinale zur Behandlung einer Krankheit, die mit Helicobacter pylori in Verbindung steht | |
| DE2009342C3 (de) | Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern | |
| DD262582A5 (de) | Ifosfamid-lyophilisat und verfahren zu dessen herstellung | |
| DE3873210T2 (de) | Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz. | |
| Köllner et al. | Psychotherapeutische Interventionen vor und nach Organtransplantation | |
| DE2911332C2 (enExample) | ||
| DE2625220A1 (de) | Arzneipraeparate mit einem gehalt an 1,3-dithiaverbindungen | |
| CH640244A5 (en) | Biologically active substance | |
| CH695417A5 (de) | Verfahren zur Umsetzung von Alkaloiden. | |
| Gedek et al. | Rachitis bei Mastgeflügel durch Kontamination des Futters mit Fusarium moniliforme Sheldon: 1. Mitteilung: Feldbeobachtungen, Reproduktion des Krankheitsbildes und Behandlungsversuche | |
| DE19817177A1 (de) | Pflanzliche Polysaccharide mit immunstimulierender Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE905882C (de) | Verfahren zur Gewinnung von Giften und Gegengiften zur Heilbehandlung entsprechender Infektionskrankheiten | |
| DE3105121C2 (de) | 1-(Phenyl)-4-diäthylcarbamoylpiperazin-Verbindungen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE60216518T2 (de) | Bioaktive hexan fraktion aus vetiveria zizanioides |